H2SITE and SNAM Collaborate on an Innovative Hydrogen and Natural Gas Separation Project Promoted by ARERA
H2SITE, a leading company in hydrogen separation technology and hydrogen transportation solutions, has announced its collaboration with SNAM, one of Europe’s key energy infrastructure operators, to develop an innovative project focused on the separation of hydrogen and natural gas mixtures.
As part of this initiative, H2SITE has designed a Pd-alloy membrane separator, capable of extracting hydrogen from 2% to 10% concentrations. Once built, this unit will represent the largest installation of its kind, capable of separating hydrogen at low concentrations while achieving high recovery rates.
The Pd-alloy membrane separator allows the recovered hydrogen to be used directly in fuel cells, hydrogen-to-power solutions such as gas turbines and engines, and high-temperature ovens. At the same time, it minimizes the hydrogen content in the remaining natural gas, preventing unwanted alterations in its composition. This is particularly important for industrial consumers whose processes cannot tolerate significant hydrogen concentrations and ensures compliance with local regulations in the gas grid. H2SITE membranes will operate at pressures above 50 bar, an industrial scale proof point relevant for large-scale hydrogen storage applications, such as salt caverns or depleted reservoirs.
H2SITE’s hydrogen separation technology has already been successfully validated with gas distribution grid operators, demonstrating the compatibility of existing distribution infrastructures with the transport of hydrogen-natural gas mixtures. It has also proven the efficient separation of hydrogen from the natural gas stream, enabling both the production of high-purity hydrogen and the removal of hydrogen from natural gas while maintaining to clean streams.
This new project reinforces H2SITE’s strategic collaboration with major infrastructure players like transmission system operators (TSOs), distribution system operators (DSOs), and other stakeholders interested in hydrogen separation. Additionally, and thanks to the support from the Italian Regulatory Authority for Energy, Networks, and Environment (ARERA), it strengthens H2SITE’s commercial presence in the Italian market, fostering collaborations and promoting the adoption of innovative technologies for the energy transition.
This initiative marks a significant step towards decarbonizing the energy sector, leveraging existing infrastructure, such as pipelines, and integrating new ones, such as salt caverns etc. to facilitate hydrogen integration as a clean and renewable energy source. Through advanced separation solutions, H2SITE and SNAM are contributing to making hydrogen a key resource for the future of sustainable energy.
About H2SITE
H2SITE, founded in 2020, is a technology company specializing in the on-site production and separation of high-purity hydrogen. The company utilizes exclusive palladium-alloy membrane reactor technology to efficiently convert various feedstocks—including ammonia, methanol, and syngas—into hydrogen. Additionally, H2SITE enables the separation of hydrogen from low-concentration gaseous mixtures for applications such as salt caverns or geologic hydrogen. By decentralizing hydrogen production through innovative ammonia cracking and separation solutions, H2SITE addresses the challenges of cost-effective hydrogen transportation and storage, significantly reducing associated costs and emissions.
About SNAM
SNAM is a leading European operator in gas infrastructure, specialized in Transportation, with a network exceeding 38,000 km across Italy and abroad; in Storage, holding one-sixth of the European Union's entire storage capacity; and in Regasification, where it ranks as the third largest European player, managing (or co-managing) an estimated annual capacity of 28 billion cubic metres, including the Ravenna LNG plant. SNAM's long-term ambition is to develop energy infrastructure for a sustainable future, positioning itself as a multi-molecule operator at both national and European levels. The company prioritizes transformative innovation and all-round sustainability as its key strategic levers, enhancing the role of gas as a transition vector. SNAM is among the top listed Italian companies by market capitalisation and is committed to continuous growth in sustainable finance.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250316570861/en/
Contacts
For more information:
Andrés Galnares, CEO of H2SITE:
andres.galnares@h2site.eu
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CCM Biosciences Announces Presentation of Data on its First-In-Class AML Drug Program at ASCO 202520.5.2025 23:30:00 EEST | Press release
CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its next-generation FLT3 inhibitor drug program for acute myeloid leukemia (AML) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. Acute Myeloid Leukemia (AML) is the most severe form of leukemia with few treatment options, and a malignancy frequently driven by mutations in the FMS-like tyrosine kinase 3 (FLT3) gene. The FLT3 internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations, particularly D835 and F691, appear in approximately 30% of AML patients, often leading to poor prognosis and resistance to existing therapies. Gilteritinib (Xospata®; Astellas Pharma, peak annual sales projection: $1.5 billion) and Quizartinib (Vanflyta®; Daiichi Sankyo) are two FDA-approved FLT3 inhibitors, with the former approved only for relapsed/refractory AML and the latter approved o
IonQ Partners with Sweden’s Einride to Develop Quantum Supply Chain and Quantum-Enhanced Logistics for Autonomous Driving Solutions20.5.2025 23:05:00 EEST | Press release
IonQ (NYSE: IONQ), a leading commercial quantum computing and networking company, today announced an investment partnership with Einride, a leading global freight mobility company that provides digital, electric, and autonomous technology to explore how quantum computing can drive the next generation of fleet optimization and logistics. Together, IonQ and Einride will develop quantum applications that address large-scale routing and scheduling problems that have traditionally challenged classical computing. By combining IonQ’s advanced quantum systems with Einride’s expertise in autonomous fleet logistics, the two companies will work to unlock new levels of efficiency, reliability, and sustainability for the global freight industry. “Einride shares our belief that quantum computing will fundamentally reshape and improve how large industries such as transportation and logistics operate,” said Niccolo de Masi, CEO of IonQ. “This partnership is aimed at creating a powerful platform with u
CCM Biosciences Announces Presentation of Data on its First-In-Class NSCLC Drug Program at ASCO 202520.5.2025 22:26:00 EEST | Press release
CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its 4th-generation EGFR inhibitor drug program for non-small cell lung cancer (NSCLC) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. NSCLC, which accounts for 80% of lung cancer, is the most common cause of cancer death worldwide. Epidermal growth factor receptor (EGFR)-activating mutations (Del19 or L858R) are major oncogenic drivers of NSCLC. EGFR-positive NSCLC accounts for approximately 30% of all diagnosed cases of NSCLC (a similar market size to PD-L1-positive NSCLC, which is addressed by the world’s top-selling drug, Keytruda®). The current standard of care for EGFR-positive NSCLC is comprised of 3rd-generation inhibitors, most notably Osimertinib (Tagrisso®), whose annual sales exceed $6 billion. Most patients treated by tyrosine kinase inhibitors (TKIs) will eventually develop
NielsenIQ's Chief Technology Officer Mohit Kapoor Named Executive of the Year at Global Tech & AI Awards for Leading NIQ’s AI-Driven Tech Transformation20.5.2025 22:24:00 EEST | Press release
NielsenIQ (NIQ) is proud to announce that Mohit Kapoor, Chief Technology Officer, was named Executive of the Year at the inaugural Global Tech & AI Awards. This honor recognizes Mohit's exceptional leadership and visionary contributions to the tech industry, particularly in the realm of AI-powered consumer intelligence. "I am deeply honored to receive the Executive of the Year award at the Global Tech & AI Awards. This recognition is a testament to the incredible work and dedication of the entire NielsenIQ team,” said Mohit Kapoor, Chief Technology Officer, NIQ. “Together, we have redefined consumer and retail intelligence, leveraging AI to deliver unparalleled insights and drive meaningful change in the industry." Under Mohit's leadership, NIQ has adopted an AI-powered approach to its ambitious digital transformation which included a $400 million technology investment and the migration of its global client base onto Discover– a unified, cloud-based platform that seamlessly integrates
Strategic Partnership Between the Government of Morocco and TAQA Morocco, Nareva, ONEE and the Mohammed VI Investment Fund to Develop Key Power and Water Infrastructures in the Kingdom of Morocco20.5.2025 22:08:00 EEST | Press release
As part of the implementation of the commitments made in the joint declaration between His Majesty King Mohammed VI, may God Assist Him, and His Highness Sheikh Mohamed bin Zayed Al Nahyan, TAQA Morocco, in partnership with Nareva and the Mohammed VI Fund for Investment, has signed three memorandums of understanding and related development agreements with the Government of Morocco and ONEE. These agreements cover the development of structuring projects in the power, water and renewable energy sectors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250520313620/en/ Strategic Partnership Between the Government of Morocco and TAQA Morocco, Nareva, ONEE and the Mohammed VI Investment Fund to Develop Key Power and Water Infrastructures in the Kingdom of Morocco (Photo: AETOSWire) The program aims to strengthen the Kingdom's water and energy sovereignty through the development of flexible natural gas-based power generation capacit
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom